Trial
NCT06773403
Upadacitinib for Prurigo Nodularis
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Psoriasis Treatment Center of Central New Jersey
Collaborators
AbbVie
Condition
Prurigo Nodularis
Intervention
Upadacitinib
Why stopped
There was not a big enough patient population to meet recruitment goals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-20